Blueprint Medicines Corp (BPMC) Stock: Deerfield Management Reports New 4.51% Stake

Page 6 of 12 – SEC Filing

Item 1(a).		Name of Issuer:
		Blueprint Medicines Corporation
Item 1(b).		Address of Issuer’s Principal Executive Offices:
		38 Sidney Street, Suite 200 Cambridge, MA 02139
Item 2(a).		Name of Person Filing:
		James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P. and Deerfield International Master Fund, L.P.
Item 2(b).		Address of Principal Business Office, or if None, Residence:
		James E. Flynn, Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., Deerfield International Master Fund, L.P. 780 Third Avenue, 37th Floor, New York, NY 10017
Item 2(c).		Citizenship:
		Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. – Delaware limited partnerships; Deerfield International Master Fund, L.P. – British Virgin Islands limited partnership; James E. Flynn – United States citizen
Item 2(d).		Title of Class of Securities:
		Common Stock
Item 2(e).		CUSIP Number:
		09627Y109
Item 3.		If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

(a)		o	Broker or dealer registered under Section 15 of the Exchange Act.
(b)		o	Bank as defined in Section 3(a)(6) of the Exchange Act.
(c)		o	Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d)		o	Investment company registered under Section 8 of the Investment Company Act.

 

(e)

o

An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)		o	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);